Étiquette : recherche

LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation, Rainer Kraehenmann et al., 2017

LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation Rainer Kraehenmann, Dan Pokorny, Helena Aicher, Katrin H. Preller, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz and Franz X. Vollenweider Frontiers in Pharmacology, 2017, Volume 8, Article 814, 1-9. Doi : 10.3389/fphar.2017.00814   Rationale : Stimulation of serotonin 2A (5-HT2A) receptors by lysergic acid diethylamide (LSD) and related compounds such as psilocybin has previously been shown to increase primary process thinking – an ontologically and evolutionary early, implicit, associative, and automatic mode of thinking which is typically occurring during altered states of consciousness such as dreaming. However, it is still largely unknown whether LSD induces [...]

Lire la suite

Cannabis and Coronavirus : What Cannabis Patients Want to Know, Rxleaf.com, February 17, 2020

Cannabis and Coronavirus : What Cannabis Patients Want to Know Jennifer Grant https://www.rxleaf.com/cannabis-and-coronavirus-what-cannabis-patients-want-to-know/ February 17, 2020 There is evidence that cannabis can reduce viral load in HIV, can it help COVID-19 patients? At the time of writing, there were 69, 287 confirmed cases of the coronavirus and 1670 deaths. With the rapid escalation of the outbreak, these numbers will surely be outdated by the time of publication. With several regions heading into states of emergencies, including quarantine, nervous travelers are looking for anti viral herbs to reduce the chance of infection. Patients have asked us: What about cannabis? There have been rumors about successful treatments for coronavirus, [...]

Lire la suite

Long-term effects of psychedelic drugs : A systematic review, Jacob S.Aday et al., 2020

Long-term effects of psychedelic drugs : A systematic review Jacob S.Adaya, Cayla M.Mitzkovitz, Emily K.Bloesch, Christopher C.Davoli, Alan K.Davis Neuroscience and Biobehavioral Reviews, 2020. Doi : 10.1016/j.neubiorev.2020.03.017   A B S T R A C T Research into the basic effects and therapeutic applications of psychedelic drugs has grown considerably in recent years. Yet, pressing questions remain regarding the substances’ lasting effects. Although individual studies have begun monitoring sustained changes, no study to-date has synthesized this information. Therefore, this systematic review aims to fill this important gap in the literature by synthesizing results from 34 contemporary experimental studies which included classic psychedelics, human subjects, and follow-up [...]

Lire la suite

IACM-Bulletin du 20 Mars 2020

IACM-Bulletin du 20 Mars 2020 IACM: 20ème Anniversaire de l'IACM IACM: Conférences IACM: Webinaires IACM: Bulletin IACM: Journaux IACM: Conseil d'administration IACM: Félicitations Un coup d'œil sur le passé IACM: 20ème Anniversaire de l'IACM Il y a 20 ans, un petit cercle de personnes a fondé l'IACM en tant qu'Association for Cannabis as Medicine, plus tard renommée Association for Cannabinoid Medicines. La 1ère conférence internationale de l'IACM sur les cannabinoïdes en médecine, qui s'est tenue à Berlin en 2001 avec l'hôpital de la Charité et l'Association médicale de Berlin, a réuni 80 participants [...]

Lire la suite

A Comparative Literature Survey of Psilocybin and LSD-25 Metabolism, Ian Joyce, 2017

A Comparative Literature Survey of Psilocybin and LSD-25 Metabolism Ian Joyce Capstone Project CHM 400 H Cal Poly Pomona, Winter 2017 | 1 - &ç   Psilocybin and lysergic acid diethylamide (LSD-25) are two of the most popular and well known psychedelic drugs. Although both of the compounds are currently illegal in the United States, a renewed interest has begun in recent years to examine and analyze these drugs for therapeutic use. This review analyzes the current research pertaining to the metabolism, biochemical pathways, receptor activity, biological signaling, physiological effects and the behavioral effects associated with both of these compounds. For psychedelic compounds to [...]

Lire la suite

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice, Andreza B. Sonego et al., 2016

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice Andreza B. Sonego; Felipe V. Gomes; Elaine A. Del Bel; Francisco S. Guimaraes Behavioural Brain Research, 2016, 21. Doi : 10.1016/j.bbr.2016.04.042   Highlights  Cannabidiol (CBD) attenuated haloperidol-induced catalepsy.  CBD reduced c-Fos protein expression in the dorsal striatum induced by haloperidol.  CBD effects were blocked by 5-HT1A receptor antagonist.   Abstract Cannabidiol (CBD) is a major non-psychoactive compound from Cannabis sativa plant. Given that CBD reduces psychotic symptoms without inducing extrapyramidal motor side-effects in animal models and schizophrenia patients, it has been proposed to act as an atypical antipsychotic. In addition, CBD [...]

Lire la suite

Psychedelics for Mental Illness: The Evidence to Date, Todd Murphy, 2020

Psychedelics for Mental Illness: The Evidence to Date Todd Murphy Medscape, 12 March, 2020. https://www.medscape.com/viewarticle/926694_print Psychedelic drugs show real promise as treatment for psychiatric illnesses, particularly posttraumatic stress disorder (PTSD) as well as depression and anxiety, new research suggests. A literature review showed completed clinical trials support the efficacy of 3, 4-methylenedioxymethamphetamine (MDMA), commonly known by its street name of Ecstasy, to treat chronic PTSD. The review also confirmed that psilocybin, a compound contained in some species of mushrooms, significantly helped in the treatment of depression and cancer-related anxiety. Other promising, though more preliminary, results suggests that the hallucinogenic drug LSD (lysergic acid diethylamide) and a plant-based brew [...]

Lire la suite

Nonlinear Disposition and Metabolic Interactions of Cannabidiol Through CYP3A Inhibition In Vivo in Rats, Michiru Nagao et al., 2020

Nonlinear Disposition and Metabolic Interactions of Cannabidiol Through CYP3A Inhibition In Vivo in Rats Michiru Nagao, Yukako Nakano, Masataka Tajima, Erika Sugiyama, Vilasinee Hirunpanich Sato, Makoto Inada, and Hitoshi Sato Cannabis and Cannabinoid Research, 2020, Volume X, Number X, 1-8. DOI: 10.1089/can.2019.0098   Abstract Introduction : Cannabidiol (CBD) is known to affect the pharmacokinetics of other drugs through metabolic inhibition of CYP2C19 and CYP3A4. However, there is a lack of in vivo evidence for such drug interactions. Therefore, we investigated the saturability of CBD metabolism and CBD-drug interactions through inhibition of CYP3A in vivo. Materials and Methods : A nanoemulsion formulation of CBD (CBD-NE) was orally administered to [...]

Lire la suite

Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats, Karina Genaro et al., 2017

Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats Karina Genaro, Débora Fabris, Ana L. F. Arantes, Antônio W. Zuardi, José A. S. Crippa and Wiliam A. Prado Frontiers in Pharmacology, June 2017 | Volume 8 | Article 391 doi : 10.3389/fphar.2017.00391   Background : Pain involves different brain regions and is critically determined by emotional processing. Among other areas, the rostral anterior cingulate cortex (rACC) is implicated in the processing of affective pain. Drugs that interfere with the endocannabinoid system are alternatives for the management of clinical pain. Cannabidiol (CBD), a phytocannabinoid found in Cannabis sativa, has been utilized [...]

Lire la suite